These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23725157)

  • 1. Risk of serious neutropenic events in cancer patients treated with bevacizumab: a meta-analysis.
    Zhou F; Shao JH; Wu LQ; Yin XB; Yu X
    Asian Pac J Cancer Prev; 2013; 14(4):2453-9. PubMed ID: 23725157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Hapani S; Wu S
    JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
    Schutz FA; Jardim DL; Je Y; Choueiri TK
    Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
    Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
    JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
    Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
    Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
    Hapani S; Sher A; Chu D; Wu S
    Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
    Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups.
    Qi WX; Fu S; Zhang Q; Guo XM
    Clin Drug Investig; 2014 Oct; 34(10):681-90. PubMed ID: 25096848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.
    Zuo PY; Chen XL; Liu YW; Xiao CL; Liu CY
    PLoS One; 2014; 9(7):e102484. PubMed ID: 25025282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis.
    Chen XL; Lei YH; Liu CF; Yang QF; Zuo PY; Liu CY; Chen CZ; Liu YW
    PLoS One; 2013; 8(6):e66721. PubMed ID: 23818962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
    Sher A; Wu S
    Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
    Hapani S; Chu D; Wu S
    Lancet Oncol; 2009 Jun; 10(6):559-68. PubMed ID: 19482548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
    Qi WX; Shen Z; Tang LN; Yao Y
    Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
    Schutz FAB; Je Y; Azzi GR; Nguyen PL; Choueiri TK
    Ann Oncol; 2011 Jun; 22(6):1404-1412. PubMed ID: 21115602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.
    Dai F; Shu L; Bian Y; Wang Z; Yang Z; Chu W; Gao S
    Clin Drug Investig; 2013 Nov; 33(11):779-88. PubMed ID: 23979925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Cao C; Wang J; Bunjhoo H; Xu Y; Fang H
    Acta Oncol; 2012 Feb; 51(2):151-6. PubMed ID: 22085338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.